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Discussion
Dr D. Craig Miller (Stanford, Calif). I congratulate Dr Farivar
and Dr Cohn for bringing something to our attention that may
prove to be very important in the future. Certainly it is scientifi-
cally much more appealing than what some of you in the room
may be old enough to remember. In the late 1970s and early 1980s,
Don Magilligan and others were saying, “We’re only going to get
so many heartbeats out of these tissue valves. Why don’t we use
-blockers and slow down their heart rates? Maybe the valves
would last longer.” Those were the old days. This is very prom-
ising and exciting, and it stems from the work being done in the
native aortic valve in elderly patients with aortic sclerosis, where
Emile Moeller at Penn and his vascular biology colleagues think
they are going to take another operation away from us. But don’t
get too paranoid, because the very promising work in elderly
patients with aortic sclerosis does not apply to younger patients
with calcific aortic sclerosis, in whom the valve was originally a
bicuspid valve. In fact, at the American Heart Association meeting
in 2002, Dr Moeller said that the Penn Institutional Review Board
believed it was unethical to randomize large cohorts of patients
with native valve aortic sclerosis. The uncontrolled data had al-
ready proved to their satisfaction that statins retard progression of
aortic sclerosis. I personally do not think that has been proven
conclusively, but that is what Moeller relayed. In any event, there
has been no information, until the material you just heard, about
what happens when patients with bioprosthetic valves are treated
with statins.
This paper was submitted early and actually has already been
revised and accepted for publication in the Journal by Andrew
Wechsler. Tirone David has written an editorial pertaining to this
paper and a similar one from Germany by Nollert and associates
concerning the effects of hyperlipidemia on the durability of the
Hancock pericardial valve. Both papers will be fast-tracked be-
cause the Editor believes this question is important.
Tirone David looked at 635 old Hancock I valves from Stan-
ford implanted in the 1970s and 1980s and observed for 15 years
or more. He could show no adverse impact of hyperlipidemia on
structural valve deterioration (SVD). He then looked at 913 pa-
tients undergoing aortic valve replacement at the Toronto General
Hospital in the 1990s (Hancock II, Carpentier-Edwards pericar-
dial, and Toronto SPV) and again could find no apparent adverse
influence of hyperlipidemia on SVD.
Some of you may have been wondering why the freedom from
SVD curves in Toronto with any kind of tissue valve are so good.
Tirone himself has admitted that maybe it is because in Ontario
almost everybody is already on a statin; maybe they never will see
an effect there in their more recent patients. Another factor per-
taining to the mitral position is that only the very sickest and very
elderly patients undergo mitral valve replacement with a tissue
bioprosthesis; the majority of valves are repaired.
In any event, this is promising work, even though it is just the
first step. I do have one statistical question: When you get down to
the case match controls, exclude the statin matches, and then you
rematch for age, you get to some very small Ns. How does this
affect the reliability of your statistics?
My real question is this: What is the next step? How are we
going to confirm that this is true or not in larger, multicenter
analyses? Tell us where you are headed. In today’s world, at least
in California, it appears that almost everybody is already on
atorvastatin calcium (Lipitor) or some statin, even if they do not
have coronary disease; therefore, how can you ever hope to test
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your hypothesis? What is the next step to obtain conclusive proof
that treatment of hypercholesterolemia into the low normal
range—and I should emphasize that the values shown here used to
be accepted as normal in the North American population B—de-
lays bioprosthetic SVD in large patient cohorts?
Dr Farivar. Dr Miller, thank you. This is the first report in
bioprosthetic valves, and to get to the truth, I think we need a
prospective randomized controlled trial. I would envision a
multicenter trial enrolling subjects who have implanted tissue
valves and subcritical coronary stenosis and are not receiving
statins. We should randomize them into two groups— one to
receive HMG-CoA reductase inhibitors and the other to receive
placebo—and to follow the progression of bioprosthetic tissue
valve calcium accumulation over 1 to 2 years, using methods
that are similar to a study recently published concerning the
native aortic valve. Shavelle and associates have recently
shown in the Lancet that statins reduce the accumulation of
calcium in the native aortic valve, as assessed by electron beam
computed tomographic scanning, for calcium in the valve. These
studies could be performed concurrently with surveillance scans of
the coronary arteries to determine whether statins also prevent the
progression of coronary calcification.
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